{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:51Z","timestamp":1791357111537,"version":"4.3.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/jcp.0b013e318224864d","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:49:40Z","timestamp":1308624580000},"page":"418-428","source":"Crossref","is-referenced-by-count":54,"title":["A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder"],"prefix":"10.1097","volume":"31","author":[{"given":"Arifulla","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Eggens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Baldytcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1017\/S0033291705006069","article-title":"Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"35","author":"Grant","year":"2005","journal-title":"Psychol Med"},{"key":"R2-4-20210128","first-page":"1362","article-title":"Generalized anxiety disorder and health care use.","volume":"51","author":"Belanger","year":"2005","journal-title":"Can Fam Physician"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2006.09.018","article-title":"Risk factors for suicidality in Europe: results from the ESEMED study.","volume":"101","author":"Bernal","year":"2007","journal-title":"J Affect Disord"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/da.1070","article-title":"Infrequency of \"pure\" GAD: impact of psychiatric comorbidity on clinical course.","volume":"14","author":"Bruce","year":"2001","journal-title":"Depress Anxiety"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/da.20249","article-title":"Impairment and quality of life in individuals with generalized anxiety disorder.","volume":"24","author":"Henning","year":"2007","journal-title":"Depress Anxiety"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1176\/ajp.156.12.1915","article-title":"Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys.","volume":"156","author":"Kessler","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"suppl 8","key":"R7-4-20210128","first-page":"24","article-title":"Generalized anxiety and depression in primary care: prevalence, recognition, and management.","volume":"63","author":"Wittchen","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"suppl 19","key":"R8-4-20210128","first-page":"5","article-title":"Dissolving the burden of generalized anxiety disorder.","volume":"62","author":"Ninan","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision.","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4088\/JCP.v66n0113","article-title":"Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline.","volume":"66","author":"Ball","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"suppl 11","key":"R12-4-20210128","first-page":"53","article-title":"Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.","volume":"62","author":"Ballenger","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"suppl 2","key":"R13-4-20210128","first-page":"24","article-title":"Treating generalized anxiety disorder.","volume":"64","author":"Gorman","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0447.2006.00896.x","article-title":"Generalized anxiety disorder: a 40-year follow-up study.","volume":"115","author":"Rubio","year":"2007","journal-title":"Acta Psychiatr Scand"},{"issue":"suppl 5","key":"R15-4-20210128","first-page":"7","article-title":"Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.","volume":"65","author":"Chouinard","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"S499","DOI":"10.1016\/S0924-977X(08)70749-1","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder (GAD) abstract.","volume":"18","author":"Merideth","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","article-title":"Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.","volume":"13","author":"Bandelow","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R18-4-20210128","first-page":"239","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD) asbtract.","volume":"10","author":"Magi","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/YIC.0b013e32833e34d9","article-title":"Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial.","volume":"26","author":"Katzman","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds.","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"issue":"suppl 1","key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0924-9338(10)71429-2","article-title":"Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties.","volume":"25","author":"Nyberg","year":"2010","journal-title":"Eur Psychiatry"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity.","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1310\/GTFR-2DRX-M6YE-ELXR","article-title":"Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000).","volume":"2","year":"2001","journal-title":"HIV Clin Trials"},{"key":"R24-4-20210128","first-page":"231","article-title":"Int Dig Health Legis.","volume":"48","year":"1997","journal-title":""},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating.","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"R27-4-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"key":"R28-4-20210128","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s11136-005-2816-9","article-title":"Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients.","volume":"14","author":"Ritsner","year":"2005","journal-title":"Qual Life Res"},{"key":"R29-4-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/00926230500232909","article-title":"Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14).","volume":"32","author":"Keller","year":"2006","journal-title":"J Sex Marital Ther"},{"key":"R30-4-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R31-4-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"R32-4-20210128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1192\/bjp.176.4.363","article-title":"Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.","volume":"176","author":"Michelson","year":"2000","journal-title":"Br J Psychiatry"},{"key":"R33-4-20210128","first-page":"293","article-title":"Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.","volume":"49","author":"Hoehn-Saric","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"R34-4-20210128","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","article-title":"Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.","volume":"50","author":"Rickels","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R35-4-20210128","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1600-0447.1997.tb09660.x","article-title":"Paroxetine efficacy in the treatment of generalized anxiety disorder.","volume":"95","author":"Rocca","year":"1997","journal-title":"Acta Psychiatr Scand"},{"key":"R36-4-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00213-008-1167-y","article-title":"Anxiety-like behaviors produced by acute fluoxetine administration in male Fischer 344 rats are prevented by prior exercise.","volume":"199","author":"Greenwood","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R37-4-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00004850-200015060-00002","article-title":"Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey.","volume":"15","author":"Wittchen","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"R38-4-20210128","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/09540260500104524","article-title":"Sleep disturbance in anxiety disorders.","volume":"17","author":"Papadimitriou","year":"2005","journal-title":"Int Rev Psychiatry"},{"issue":"suppl 10","key":"R39-4-20210128","first-page":"33","article-title":"Consequences of insomnia and its therapies.","volume":"62","author":"Benca","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R40-4-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1034\/j.1600-0447.2000.101001029.x","article-title":"Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity?","volume":"101","author":"Maier","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"R41-4-20210128","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/da.20740","article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.","volume":"27","author":"Liebowitz","year":"2010","journal-title":"Depress Anxiety"},{"key":"R42-4-20210128","first-page":"225","article-title":"Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD) abstract.","volume":"10","author":"Katila","year":"2009","journal-title":"World J Biol Psychiatry"},{"key":"R43-4-20210128","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jad.2010.06.031","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study published online ahead of print August 4, 2010.","volume":"128","author":"Bortnick","year":"2011","journal-title":"J Affect Disord"},{"key":"R44-4-20210128","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.08m04592","article-title":"Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.","volume":"70","author":"Cutler","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R45-4-20210128","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S1092852900020307","article-title":"Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study.","volume":"14","author":"Weisler","year":"2009","journal-title":"CNS Spectr"},{"key":"R46-4-20210128","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.08m04629","article-title":"Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.","volume":"70","author":"Bauer","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R47-4-20210128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1017\/S1461145710000015","article-title":"Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.","volume":"13","author":"El-Khalili","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R48-4-20210128","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1176\/appi.ajp.162.6.1171","article-title":"Quality-of-life impairment in depressive and anxiety disorders.","volume":"162","author":"Rapaport","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R49-4-20210128","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4088\/JCP.v68n0603","article-title":"Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study.","volume":"68","author":"Kahn","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R50-4-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900026651","article-title":"Implications of the CATIE trial on treatment: extrapyramidal symptoms.","volume":"11","author":"Casey","year":"2006","journal-title":"CNS Spectr"},{"issue":"suppl 3","key":"R51-4-20210128","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","article-title":"Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.","volume":"13","author":"Barnes","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"R52-4-20210128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/j.1440-1614.2004.01382.x","article-title":"Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.","volume":"38","author":"Sachdev","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"key":"R53-4-20210128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/026988119801200212","article-title":"SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.","volume":"12","author":"Lane","year":"1998","journal-title":"J Psychopharmacol"},{"key":"R54-4-20210128","doi-asserted-by":"crossref","first-page":"959","DOI":"10.4088\/JCP.v65n0712","article-title":"Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate.","volume":"65","author":"Hu","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R55-4-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/10401239509149625","article-title":"Clinical implications of antidepressant drug effects on sexual function.","volume":"7","author":"Harvey","year":"1995","journal-title":"Ann Clin Psychiatry"},{"key":"R56-4-20210128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Association, American Psychiatric Association, American Association of Clinical Endocrinologists. Consensus development conference on antipsychotic drugs and obesity and diabetes.","volume":"27","year":"2004","journal-title":"Diabetes Care"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201108000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:32:02Z","timestamp":1786044722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201108000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318224864d","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}